Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
PaperCitations, authors & open-access status
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 206 citations, 2023 year and closed oa status.
206
Citations
2023
Year
closed
OA Status